7.49
-0.18 (-2.35%)
| Previous Close | 7.67 |
| Open | 7.62 |
| Volume | 1,290,022 |
| Avg. Volume (3M) | 4,001,015 |
| Market Cap | 775,836,672 |
| Price / Sales | 21.16 |
| Price / Book | 1.27 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -726.57% |
| Diluted EPS (TTM) | -5.23 |
| Quarterly Revenue Growth (YOY) | -42.50% |
| Total Debt/Equity (MRQ) | 15.29% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -377.15 M |
| Levered Free Cash Flow (TTM) | -150.18 M |
| Return on Assets (TTM) | -30.12% |
| Return on Equity (TTM) | -57.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Intellia Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.01% |
| % Held by Institutions | 97.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 31 Mar 2025 | 3,702,995 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 68.00 (Chardan Capital, 807.88%) | Buy |
| Median | 30.00 (300.53%) | |
| Low | 10.00 (Wedbush, 33.51%) | Hold |
| 10.00 (Citigroup, 33.51%) | Hold | |
| Average | 34.00 (353.94%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 8.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Jun 2025 | 30.00 (300.53%) | Buy | 8.96 |
| 29 May 2025 | 30.00 (300.53%) | Buy | 7.45 | |
| Canaccord Genuity | 03 Jun 2025 | 54.00 (620.96%) | Buy | 7.69 |
| Wedbush | 19 May 2025 | 10.00 (33.51%) | Hold | 9.06 |
| Guggenheim | 12 May 2025 | 45.00 (500.80%) | Buy | 8.55 |
| Chardan Capital | 09 May 2025 | 68.00 (807.88%) | Buy | 8.12 |
| Citigroup | 09 May 2025 | 10.00 (33.51%) | Hold | 8.12 |
| Wolfe Research | 21 Apr 2025 | 21.00 (180.37%) | Buy | 7.92 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |